- Home
- BRNS vs NRXP Comparison
BRNS vs NRXP Comparison
Compare BRNS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- NRXP
- Stock Information
- Founded
- BRNS 2016
- NRXP 2015
- Country
- BRNS United Kingdom
- NRXP United States
- Employees
- BRNS N/A
- NRXP N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- NRXP Health Care
- Exchange
- BRNS Nasdaq
- NRXP Nasdaq
- Market Cap
- BRNS 58.0M
- NRXP 58.5M
- IPO Year
- BRNS 2021
- NRXP N/A
- Fundamental
- Price
- BRNS $1.61
- NRXP $3.64
- Analyst Decision
- BRNS Strong Buy
- NRXP Strong Buy
- Analyst Count
- BRNS 1
- NRXP 5
- Target Price
- BRNS $3.00
- NRXP $31.40
- AVG Volume (30 Days)
- BRNS 248.2K
- NRXP 421.9K
- Earning Date
- BRNS 11-05-2025
- NRXP 11-13-2025
- Dividend Yield
- BRNS N/A
- NRXP N/A
- EPS Growth
- BRNS N/A
- NRXP N/A
- EPS
- BRNS N/A
- NRXP N/A
- Revenue
- BRNS $14,969,000.00
- NRXP N/A
- Revenue This Year
- BRNS N/A
- NRXP N/A
- Revenue Next Year
- BRNS N/A
- NRXP $395.09
- P/E Ratio
- BRNS N/A
- NRXP N/A
- Revenue Growth
- BRNS 1766.46
- NRXP N/A
- 52 Week Low
- BRNS $0.64
- NRXP $1.10
- 52 Week High
- BRNS $2.92
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- BRNS 65.26
- NRXP 72.98
- Support Level
- BRNS $1.36
- NRXP $3.19
- Resistance Level
- BRNS $1.67
- NRXP $3.48
- Average True Range (ATR)
- BRNS 0.17
- NRXP 0.21
- MACD
- BRNS 0.05
- NRXP 0.05
- Stochastic Oscillator
- BRNS 72.15
- NRXP 80.10
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.